ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Studies Show Bayer, Boehringer Ingelheim Drugs Slow GIST, Lung-Cancer Growth

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES CHICAGO -(Dow Jones)- A study involving an experimental Bayer AG (BAYRY, BAYN.XE) cancer drug, regorafenib, showed it delayed the progression of a rare type of gastrointestinal tumor in patients who had been previously treated with other drugs. BayerHealthcare, a Bayer unit, announced last month that it had submitted an application to the U.S. Food and Drug Administration seeking approval for regorafenib to treat patients with advanced colon cancer, and plans to submit an application as a treatment for gastrointestinal stromal tumors, or GIST, later this year. The study looking at regorafenib in GIST involved 199 patients who had been previously treated with Novartis AG's (NVS, NOVN.VX) Gleevec or Pfizer Inc.'s (PFE) Sutent. The patients tumors had become resistant to Gleevec and Sutent, which is not uncommon as cancer finds new ways to grow. Researchers, led by George Demetri of the Dana-Farber Cancer Institute in Boston, said regorafenib targets an enzyme called KIT along with other pathways cancer uses to grow. Two-thirds of the patients were given regorafenib while one-third of the patients were given a placebo drug. The study was designed to measure progression-free survival, which is a measurement of the time from the start of treatment until the disease gets worse or the patient dies. Patients in the placebo were offered regorafenib if their disease progressed. The study showed median progression-free survival was 4.8 months in the patients receiving regorafenib compared with 0.9 month for patients in the placebo group. Because most patients in the placebo group were later treated with regorafenib, there was no statistically significant difference in overall survival, Dr. Demetri said. The most common drug side-effects were hand-foot skin reactions like redness, swelling and pain, high blood pressure and diarrhea. Separately, a study looking at another experimental drug afatinib, which is being developed by Boehringer Ingelheim Pharmaceuticals Inc. for use in some types of lung cancer, showed it slowed disease progression. The study, also due for presentation Monday at ASCO, involved 345 patients whose cancers tested positive for a mutation called EGFR. That type of lung cancer is commonly seen in people who have never smoked and are of Asian descent. About two thirds of the patients received afatinib and one-third received a combination of chemotherapy drugs pemetrexed and cisplatin, common lung-cancer treatments. The study showed patients treated with afatinib had a median progression-free survival of 11.1 months compared to 6.9 months for the chemotherapy group. Overall survival data aren't expected for about two years. -By Jennifer Corbett Dooren, Dow Jones Newswires; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/25/201507:06:02Are Biosimilars the Next Big Thing in Biotech?
04/23/201518:21:48ADR Shares End Higher; Ericsson Drops, Logitech Rises
04/23/201512:49:55Eli Lilly Results Top Expectations
04/23/201512:44:52Eli Lilly Results Top Expectations
04/23/201512:32:22Novartis Begins to See Benefits of Overhaul -- 2nd Update
04/23/201506:59:03Novartis Begins to See Benefits of Overhaul -- Update
04/23/201503:58:06Novartis Profit Boosted by Disposals
04/23/201502:54:59Novartis Profit Boosted by Disposals
04/22/201519:20:35CSL Says CFO Naylor to Lead Influenza-Vaccine Business
04/22/201510:03:023 Soaring Biotech Stocks Under $10 -- Are They Buys?
04/20/201518:59:29Why Shares of Juno Therapeutics Inc. and Kite Pharma Inc. Crashed...
04/20/201517:43:06Novartis 1Q 2015 -- Forecast
04/19/201507:14:033 Megatrends in Healthcare
04/18/201509:19:03Meet the Game-Changing Drug Designed to Fight America's Leading...
04/16/201517:15:08Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher
04/16/201516:51:37FDA Approves Generic Multiple-Sclerosis Drug by Novartis's Sandoz...
04/16/201516:07:15FDA Approves Novartis and Momenta's Generic Multiple-Sclerosis...
04/16/201508:58:023 Potential Blockbuster Drugs That Could Be Approved Before Year's...
04/15/201508:59:033 Biotech Stocks That May Disappear Before 2020
04/14/201508:44:32The Growing Business Of Animal Healthcare

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad